Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedAug 16, 2025
DataAggregated Company Financials
Companies297
  • 7D6.3%
  • 3M3.8%
  • 1Y-12.2%
  • YTD-2.3%

The Pharma industry is up 6.3% in the last week, with Eli Lilly up 12%. However, the industry is down 12% over the past year. Earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 16 Aug 2025US$1.7tUS$387.8bUS$61.0b18.9x28.1x4.4x
Mon, 14 Jul 2025US$1.8tUS$382.7bUS$61.3b18.1x28.8x4.6x
Wed, 11 Jun 2025US$1.7tUS$382.7bUS$61.2b18.2x28.3x4.5x
Fri, 09 May 2025US$1.7tUS$383.0bUS$64.0b16.7x26.7x4.5x
Sun, 06 Apr 2025US$1.7tUS$379.9bUS$41.3b16x40.4x4.4x
Tue, 04 Mar 2025US$2.0tUS$381.1bUS$39.3b16.8x49.8x5.1x
Thu, 30 Jan 2025US$1.8tUS$370.2bUS$29.9b19.6x61.7x5x
Sat, 28 Dec 2024US$1.8tUS$369.4bUS$31.1b16.9x58.4x4.9x
Mon, 25 Nov 2024US$1.8tUS$373.8bUS$30.6b20.5x59.3x4.8x
Wed, 23 Oct 2024US$2.0tUS$365.3bUS$23.7b18.2x84.6x5.5x
Fri, 20 Sep 2024US$2.0tUS$364.2bUS$25.4b19x80.3x5.6x
Sun, 18 Aug 2024US$2.0tUS$362.1bUS$21.8b17.3x91.7x5.5x
Tue, 16 Jul 2024US$2.0tUS$357.7bUS$13.8b15.9x146.1x5.7x
Thu, 13 Jun 2024US$1.9tUS$358.3bUS$14.1b15.8x138.1x5.4x
Sat, 11 May 2024US$1.9tUS$358.2bUS$13.5b18.5x137.7x5.2x
Mon, 08 Apr 2024US$1.9tUS$355.2bUS$22.8b24.7x82.2x5.3x
Wed, 06 Mar 2024US$1.9tUS$355.3bUS$22.5b23.4x84.5x5.3x
Fri, 02 Feb 2024US$1.8tUS$353.0bUS$22.3b32x80.4x5.1x
Sun, 31 Dec 2023US$1.7tUS$375.2bUS$33.8b31.9x49.9x4.5x
Tue, 28 Nov 2023US$1.7tUS$375.1bUS$33.9b26x48.8x4.4x
Thu, 26 Oct 2023US$1.7tUS$382.7bUS$44.7b14.9x36.9x4.3x
Sat, 23 Sep 2023US$1.7tUS$381.8bUS$43.9b19.9x38.3x4.4x
Mon, 21 Aug 2023US$1.8tUS$381.6bUS$44.1b18.5x40.4x4.7x
Wed, 19 Jul 2023US$1.7tUS$392.8bUS$60.2b18.9x27.6x4.2x
Fri, 16 Jun 2023US$1.7tUS$392.8bUS$60.1b19.2x28.7x4.4x
Sun, 14 May 2023US$1.7tUS$392.9bUS$60.4b20.4x28.7x4.4x
Tue, 11 Apr 2023US$1.7tUS$401.3bUS$69.7b16.7x23.7x4.1x
Thu, 09 Mar 2023US$1.5tUS$401.2bUS$69.3b16.8x22.3x3.8x
Sat, 04 Feb 2023US$1.7tUS$402.1bUS$69.9b18.2x23.7x4.1x
Mon, 02 Jan 2023US$1.7tUS$403.7bUS$70.7b16.8x24.7x4.3x
Wed, 30 Nov 2022US$1.7tUS$403.7bUS$70.7b16.7x24.7x4.3x
Fri, 28 Oct 2022US$1.7tUS$404.8bUS$70.8b13.6x23.6x4.1x
Sun, 25 Sep 2022US$1.6tUS$403.0bUS$71.3b12.8x21.9x3.9x
Tue, 23 Aug 2022US$1.6tUS$402.8bUS$70.1b14.8x23.5x4.1x
Price to Earnings Ratio

23.5x


Total Market Cap: US$1.6tTotal Earnings: US$70.1bTotal Revenue: US$402.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.1x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 28.1x which is lower than its 3-year average PE of 52.1x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 4.5% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.01%
Healthcare4.85%
Pharma6.27%
Pharma6.27%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$701.2312.1%
+US$67.9b		-24.0%PE45.6x
MRK MerckUS$84.214.4%
+US$8.8b		-25.9%PE12.8x
JNJ Johnson & JohnsonUS$176.641.9%
+US$8.0b		10.8%PE18.8x
BMY Bristol-Myers SquibbUS$48.445.4%
+US$5.1b		-1.9%PE19.5x
PFE PfizerUS$25.142.3%
+US$3.2b		-11.2%PE13.3x

Latest News

MRK
US$84.21
Merck
7D
4.4%
1Y
-25.9%
LLY
US$701.23
Eli Lilly
7D
12.1%
1Y
-24.0%
ALTS
US$5.94
ALT5 Sigma
7D
-33.8%
1Y
161.7%
RPRX
US$36.35
Royalty Pharma
7D
-3.3%
1Y
33.8%
ZVRA
US$9.43
Zevra Therapeutics
7D
-21.5%
1Y
28.0%
PFE
US$25.14
Pfizer
7D
2.3%
1Y
-11.2%

Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business
VTRS
US$10.61
Viatris
7D
9.4%
1Y
-9.0%
SIGA
US$8.50
SIGA Technologies
7D
-5.1%
1Y
-19.0%

SIGA Technologies, Inc.'s (NASDAQ:SIGA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Aug 08
SIGA Technologies, Inc.'s (NASDAQ:SIGA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
BLTE
US$66.63
Belite Bio
7D
-4.7%
1Y
33.4%
CORT
US$71.75
Corcept Therapeutics
7D
-0.8%
1Y
111.2%
TEVA
US$17.86
Teva Pharmaceutical Industries
7D
9.1%
1Y
-2.2%
ZTS
US$154.11
Zoetis
7D
4.6%
1Y
-16.1%
BMY
US$48.44
Bristol-Myers Squibb
7D
5.4%
1Y
-1.9%
JNJ
US$176.64
Johnson & Johnson
7D
1.9%
1Y
10.8%
ATAI
US$3.88
Atai Life Sciences
7D
-6.1%
1Y
218.0%

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28
RGC
US$13.12
Regencell Bioscience Holdings
7D
-6.1%
1Y
5,821.2%